U.S., Dec. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07287189) titled 'Phase 2, Randomized, Placebo-controlled Proof-of-concept Study of SAT-3247 in Pediatric Ambulatory Patients' on Dec. 11.
Brief Summary: Phase 2a trial of SAT-3247 in ambulatory DMD patients aged >= 7 and < 10 years. The trial will study two doses of SAT-3247 in a randomized, double-blind, placebo-controlled weekday regimen for 12 weeks to determine the optimal dose, safety, tolerability, and preliminary efficacy.
Study Start Date: Dec. 08
Study Type: INTERVENTIONAL
Condition:
Duchenne Muscular Dystrophy
Duchenne
DMD
Neuromuscular Diseases
Muscular Dystrophies
Intervention:
DRUG: SAT-3247
SAT-3247 is a selective AAK1 inhibitor...